TY - JOUR
T1 - SARS–CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases
T2 - A Systematic Literature Review and Meta-Analysis
AU - the COVID-19 Global Rheumatology Alliance
AU - Conway, Richard
AU - Grimshaw, Alyssa A.
AU - Konig, Maximilian F.
AU - Putman, Michael
AU - Duarte-García, Alí
AU - Tseng, Leslie Yingzhijie
AU - Cabrera, Diego M.
AU - Chock, Yu Pei Eugenia
AU - Degirmenci, Huseyin Berk
AU - Duff, Eimear
AU - Egeli, Bugra Han
AU - Graef, Elizabeth R.
AU - Gupta, Akash
AU - Harkins, Patricia
AU - Hoyer, Bimba F.
AU - Jayatilleke, Arundathi
AU - Jin, Shangyi
AU - Kasia, Christopher
AU - Khilnani, Aneka
AU - Kilian, Adam
AU - Kim, Alfred H.J.
AU - Lin, Chung Mun Alice
AU - Low, Candice
AU - Proulx, Laurie
AU - Sattui, Sebastian E.
AU - Singh, Namrata
AU - Sparks, Jeffrey A.
AU - Tam, Herman
AU - Ugarte-Gil, Manuel F.
AU - Ung, Natasha
AU - Wang, Kaicheng
AU - Wise, Leanna M.
AU - Yang, Ziyi
AU - Young, Kristen J.
AU - Liew, Jean W.
AU - Grainger, Rebecca
AU - Wallace, Zachary S.
AU - Hsieh, Evelyn
N1 - Publisher Copyright:
© 2021 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2022/5
Y1 - 2022/5
N2 - Objective: The relative risk of SARS–CoV-2 infection and COVID-19 disease severity among people with rheumatic and musculoskeletal diseases (RMDs) compared to those without RMDs is unclear. This study was undertaken to quantify the risk of SARS–CoV-2 infection in those with RMDs and describe clinical outcomes of COVID-19 in these patients. Methods: We conducted a systematic literature review using 14 databases from January 1, 2019 to February 13, 2021. We included observational studies and experimental trials in RMD patients that described comparative rates of SARS–CoV-2 infection, hospitalization, oxygen supplementation/intensive care unit (ICU) admission/mechanical ventilation, or death attributed to COVID-19. Methodologic quality was evaluated using the Joanna Briggs Institute critical appraisal tools or the Newcastle-Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated, as applicable for each outcome, using the Mantel-Haenszel formula with random effects models. Results: Of the 5,799 abstracts screened, 100 studies met the criteria for inclusion in the systematic review, and 54 of 100 had a low risk of bias. Among the studies included in the meta-analyses, we identified an increased prevalence of SARS–CoV-2 infection in patients with an RMD (RR 1.53 [95% CI 1.16–2.01]) compared to the general population. The odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and those without an RMD, whereas the mortality rate was increased in patients with RMDs (OR 1.74 [95% CI 1.08–2.80]). In a smaller number of studies, the adjusted risk of outcomes related to COVID-19 was assessed, and the results varied; some studies demonstrated an increased risk while other studies showed no difference in risk in patients with an RMD compared to those without an RMD. Conclusion: Patients with RMDs have higher rates of SARS–CoV-2 infection and an increased mortality rate.
AB - Objective: The relative risk of SARS–CoV-2 infection and COVID-19 disease severity among people with rheumatic and musculoskeletal diseases (RMDs) compared to those without RMDs is unclear. This study was undertaken to quantify the risk of SARS–CoV-2 infection in those with RMDs and describe clinical outcomes of COVID-19 in these patients. Methods: We conducted a systematic literature review using 14 databases from January 1, 2019 to February 13, 2021. We included observational studies and experimental trials in RMD patients that described comparative rates of SARS–CoV-2 infection, hospitalization, oxygen supplementation/intensive care unit (ICU) admission/mechanical ventilation, or death attributed to COVID-19. Methodologic quality was evaluated using the Joanna Briggs Institute critical appraisal tools or the Newcastle-Ottawa scale. Risk ratios (RRs) and odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated, as applicable for each outcome, using the Mantel-Haenszel formula with random effects models. Results: Of the 5,799 abstracts screened, 100 studies met the criteria for inclusion in the systematic review, and 54 of 100 had a low risk of bias. Among the studies included in the meta-analyses, we identified an increased prevalence of SARS–CoV-2 infection in patients with an RMD (RR 1.53 [95% CI 1.16–2.01]) compared to the general population. The odds of hospitalization, ICU admission, and mechanical ventilation were similar in patients with and those without an RMD, whereas the mortality rate was increased in patients with RMDs (OR 1.74 [95% CI 1.08–2.80]). In a smaller number of studies, the adjusted risk of outcomes related to COVID-19 was assessed, and the results varied; some studies demonstrated an increased risk while other studies showed no difference in risk in patients with an RMD compared to those without an RMD. Conclusion: Patients with RMDs have higher rates of SARS–CoV-2 infection and an increased mortality rate.
UR - http://www.scopus.com/inward/record.url?scp=85127226306&partnerID=8YFLogxK
U2 - 10.1002/art.42030
DO - 10.1002/art.42030
M3 - Artículo
C2 - 34807517
AN - SCOPUS:85127226306
SN - 2326-5191
VL - 74
SP - 766
EP - 775
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 5
ER -